Andropause symptoms in men: what changes after 40

Most men begin experiencing hormonal changes between 40 and 55. That is the typical andropause age range. It does not arrive as a single event with a clear start date.

Testosterone production begins declining in the early 30s and continues gradually over the following decades. A 2021 systematic review in International Journal of Environmental Research and Public Health found that chronic occupational stress can accelerate the pace of hormonal symptoms in this window. By the mid-40s or early 50s, the cumulative drop often becomes significant enough to affect daily function, sleep, body composition, and sexual health. Individual variation is wide. One man may feel the shift at 42; another not until his late 50s.

The andropause symptoms men over 40 most commonly report span multiple body systems. They build gradually, which is why many men attribute them to stress or aging rather than a hormonal shift.

A 2023 study in American Journal of Men's Health found that more than 480,000 men over 40 experience andropause, with severity ranging from mild to severe. The same study noted measurable effects on sexual quality of life.

Because these signs overlap with many other conditions, symptoms alone are not enough to confirm the diagnosis. Labs measure it. A single total testosterone reading may not capture the full picture either. Free testosterone and binding protein levels together give providers a clearer view, which is why how SHBG shapes your free testosterone result matters before your first provider conversation.

The core difference is speed and permanence. Female menopause ends ovarian function permanently, typically after age 48, and usually unfolds over a few years. Andropause is a gradual, decades-long decline in testicular hormone output that never fully stops.

A 2021 study in Health Psychology Reports noted several key distinctions. Men's gonadal hormone output continues into old age, whereas women's ovarian function ceases entirely. There are also no standardized clinical staging criteria for andropause comparable to menopause evaluation tools. Hormonal variation between men is wide, and symptoms are individual.

The ambiguity does not make the condition less real. It makes diagnosis more nuanced.

Yes. The 2025 European Association of Urology guidelines on male hypogonadism classify it as a recognized and treatable condition. That was not always the consensus. Earlier medical thinking treated age-related testosterone decline as biology rather than a clinical problem. That position has shifted.

A 2015 review in World Journal of Clinical Cases found significant evidence linking hypogonadism in adult men to sexual dysfunction, cognitive decline, depression, and elevated risk of bone fractures and cardiovascular events. Those are not minor complaints. They are documented health consequences of untreated low testosterone over 40. What persists as myth is the idea that andropause resolves on its own or that its presentation is the same across all men.

Recognizing the andropause symptoms men develop often matters more for long-term outcomes than the initial severity. Low testosterone over 40 does not stay confined to fatigue and libido changes. A 2023 review in Frontiers in Endocrinology confirmed that complications of male hypogonadism include cardiovascular disease, metabolic dysfunction, and osteoporosis. The 2015 World Journal of Clinical Cases review also identified links between untreated hypogonadism and coronary artery disease, stroke, and all-cause mortality.

The case for early assessment is straightforward. Waiting does not resolve the symptoms. It allows secondary complications to develop over time.

TRT for low testosterone works by restoring circulating testosterone to a level the body can use. When levels return to a healthy baseline, downstream effects across multiple systems follow.

A 2019 survey published in International Journal of Environmental Research and Public Health found that increased energy was the most widely valued benefit of TRT, cited by about 28.6% of participants. Improved libido, better erections, more frequent sexual activity, and a stronger sense of overall well-being were also commonly reported.

A 2009 review in Therapeutics and Clinical Risk Management found that TRT improves sexual function, lean body mass, muscle strength, bone mineral density, and cognitive function. More recently, a 2024 meta-analysis in Expert Opinion on Drug Safety provided an updated assessment of cardiovascular safety for men on provider-monitored TRT.

Male hormone replacement therapy starts with labs. A licensed provider reviews testosterone, free testosterone, SHBG, LH, FSH, PSA, and hematocrit before determining any protocol. A licensed provider determines the dose after that full review. A 2024 systematic review in Health Technology Assessment confirmed that multiple treatment forms are effective for men with documented hypogonadism.

TRT is not the only andropause treatment option. A 2022 systematic review in Andrology found that clomiphene citrate is a documented alternative for men with hypogonadism who want to preserve natural testosterone production or avoid exogenous testosterone. The right path depends on lab results, health history, and individual goals.

Andropause treatment options begin with a structured evaluation. Labs come first. The provider reviews the full hormone panel, then recommends a therapy type based on what the results show. Understanding which markers your provider assesses in a hormone evaluation helps set realistic expectations going in.

Lifestyle factors run alongside medical treatment. A 2023 review in Nutrition and Health found associations between dietary protein intake and testosterone levels, suggesting that nutrition is one modifiable factor within a broader management plan. Regular resistance training, adequate sleep, and stress reduction each affect the hormonal environment independently of any medication.

Vita Bella connects men with provider-supported hormone programs built around their labs and symptoms. Providers across 47 states follow a structured intake process: labs first, then a 45-minute consultation to review results and discuss options.